Fred Feldman
Hoofd Techniek/Wetenschap/O&O bij Teva Spanish Holdco, Inc.
Profiel
Fred Feldman is Vice President of Pre-Clinical Research & Development of Bentlry Pharmaceuticals, Inc. and Chief Scientific Officer and Senior Vice President of CPEX Pharmaceuticals, Inc. Previously, he was Vice President of Pre-Clinical R&D at Armour Pharmaceutical and Senior Vice President-Worldwide, Head-Pre-Clinical R&D and Head of Biotechnology for Centeon LLC and Aventis Behring.
Dr. Feldman received a BS degree in Biochemistry from the University of Chicago and a PhD degree in Biochemistry from Purdue University.
Actieve functies van Fred Feldman
| Bedrijven | Functie | Begin |
|---|---|---|
Teva Spanish Holdco, Inc.
 Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Hoofd Techniek/Wetenschap/O&O | 01-10-2005 |
Eerdere bekende functies van Fred Feldman
| Bedrijven | Functie | Einde |
|---|---|---|
CPEX Pharmaceuticals, Inc.
 CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Hoofd Techniek/Wetenschap/O&O | 01-02-2010 |
| Centeon LLC | Hoofd Techniek/Wetenschap/O&O | - |
| Aventis Behring | Corporate Officer/Principal | - |
| Armour Pharmaceutical Co. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Fred Feldman
| The University of Chicago | Undergraduate Degree |
| Purdue University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Teva Spanish Holdco, Inc.
Teva Spanish Holdco, Inc. Pharmaceuticals: MajorHealth Technology Teva Spanish Holdco, Inc. manufactures, markets, and distributes pharmaceutical products. It specializes in offering treatment for cardiovascular, gastrointestinal, infectious, and neurological diseases. The firm was founded in 1974, and is headquartered in Exeter, NH. | Health Technology |
| Armour Pharmaceutical Co. | |
| Centeon LLC | |
| Aventis Behring | Health Technology |
CPEX Pharmaceuticals, Inc.
CPEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology CPEX Pharmaceuticals, Inc. is engaged in the development, licensing and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through formulation development with proprietary molecules such as CPE-215. The company's first product is Testim, a gel for testosterone replacement therapy, which is a formulation of its technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc., which is currently marketing it in the United States, Europe and other countries. Its other product is Nasulin, which is an intranasal formulation of insulin being developed to treat hyperglycemia in patients suffering from Type 1 and Type 2 diabetes. The company was founded on September 28, 2007 and is headquartered in Exeter, NH. | Health Technology |
